Assessment of genomic instability in normal and diabetic rats treated with metformin

S M Attia1, G K Helal, A A Alhaider

  • 1Department of Pharmacology, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia. attiasm@yahoo.com

Insights

Metformin, an anti-diabetic drug, was found to be non-genotoxic and non-cytotoxic in rats. It also protected against hyperglycemia-induced genomic instability and oxidative stress, suggesting antigenotoxic properties beyond its anti-diabetic effects.

Area of Science:

  • Pharmacology
  • Toxicology
  • Genetics

Background:

  • Metformin is a widely used biguanide anti-diabetic agent.
  • Concerns exist regarding the potential genotoxic and cytotoxic effects of anti-diabetic drugs.
  • Hyperglycemia can induce genomic instability and oxidative stress.

Purpose of the Study:

  • To evaluate the genotoxic and cytotoxic potential of metformin in normal and diabetic rats.
  • To investigate metformin's effect on hyperglycemia-induced genomic instability and oxidative stress.

Main Methods:

  • Standard cytogenetic assays (micronuclei, chromosome aberrations, mitotic activity, sperm-head anomaly) were performed.
  • Oxidative stress markers (lipid peroxidation, reduced glutathione) were assessed.
  • Single and multiple oral doses of metformin were administered to streptozotocin-induced diabetic and normal rats.

Main Results:

  • Metformin demonstrated no genotoxic or cytotoxic effects at any tested dose.
  • Metformin significantly reduced diabetes-induced genomic instability and altered cell proliferation in a dose-dependent manner.
  • Metformin treatment ameliorated oxidative stress markers, reducing lipid peroxidation and increasing reduced glutathione levels.

Conclusions:

  • Metformin is a safe compound regarding genotoxicity and cytotoxicity.
  • Metformin exhibits protective effects against hyperglycemia-induced genomic instability.
  • Metformin's radical scavenger properties may contribute to its antigenotoxic effects, complementing its anti-diabetic action.

Related Concept Videos

Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
Type II Diabetes I: Introduction01:26

Type II Diabetes I: Introduction

Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, in which target tissues such as the liver, muscle, and adipose tissue respond poorly to insulin. It is also associated with inadequate compensatory insulin secretion, where pancreatic β-cells fail to produce sufficient insulin. Together, these abnormalities lead to persistent hyperglycemia.EtiologyT2DM develops through a complex interaction of genetic predisposition and environmental or...
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...